Hemin

Phase 2Small molecule

TThe University of Texas Medical Branch, Galveston

Hemin is one of 73 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

Diabetes MellitusActive, not recruiting

Acute PancreatitisPhase 2

Active, not recruiting

Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

286 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

Xylocaine

CCitius Pharmaceuticals, Inc.

Phase 3

—3

Hypoglycemic Agents

SScotmann Pharmaceuticals

Phase 3

1 4

Trulicity

Eli Lilly

Preclinical

2 5

Byetta

AstraZeneca

Preclinical

2 6

Paxil CR

GSK

Preclinical

1 7

Edarbi

Takeda

Preclinical

1 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Galvus

Novartis

Preclinical

1 10

Simponi

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Active, not recruiting

Acute Porphyria

NCT02935400

Clinical

Trials by Indication[1]

Acute Porphyria1 trial

Acute Porphyria Biomarkers for Disease Activity

Active, not recruiting·TThe University of Texas Medical Branch, Galveston··NCT02935400·50 enrolled

Prevention1 trial

Panhematin for Prevention of Acute Attacks of Porphyria

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT02922413·13 enrolled

Diabetes Mellitus1 trial

A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

Completed·MMayo Clinic·Phase 2·NCT01206582·20 enrolled

Acute Pancreatitis1 trial

Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis

Completed·EErasme University Hospital·Phase 2·NCT01855841·284 enrolled

Unspecified1 trial

Hemin in Healthy Subjects

Completed·MMayo Clinic·Phase 1·NCT00882804·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Hemin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hemin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hemin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Medical Branch, Galveston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe University of Texas Medical Branch, Galveston

Hemin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute Porphyria1 trial

Prevention1 trial

Diabetes Mellitus1 trial

Acute Pancreatitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News